



Universiteit  
Leiden  
The Netherlands

## Clinical and molecular aspects of MUTYH- and APC-associated polyposis

Nielsen, M.

### Citation

Nielsen, M. (2011, March 10). *Clinical and molecular aspects of MUTYH- and APC-associated polyposis*. Retrieved from <https://hdl.handle.net/1887/16611>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/16611>

**Note:** To cite this publication please use the final published version (if applicable).

## 4.5

### ***MUTYH*-associated polyposis carcinomas frequently lose HLA class I expression-a common event amongst DNA-repair-deficient colorectal cancers**

de Miranda NF

Nielsen M

Pereira D

van Puijenbroek M

Vasen HF

Hes FJ

van Wezel T

Morreau H

## ABSTRACT

Human leukocyte antigen (HLA) class I expression defects frequently occur in colorectal cancers bearing mismatch repair (MMR) deficiencies and are interpreted as immune evasion mechanisms to avoid cancer cell recognition and elimination by the immune system. MMR-deficient tumours are thought to be more prone to lose HLA class I expression, due to their frequent generation of aberrant peptides which can stimulate a cytotoxic T-cell-mediated response. *MUTYH*-associated polyposis (MAP) is a colorectal cancer syndrome caused by defects in the *MUTYH* DNA repair enzyme. Impairment of *MUTYH* activity could lead to a surplus of mutated peptides which would be presented to cytotoxic T-cells through the HLA class I molecules. We have studied the frequency of HLA class I expression defects in MAP carcinomas and have compared it to those observed in MMR-deficient and -proficient colorectal tumours. Immunohistochemical detection of the expression of HLA class I,  $\beta$ 2-microglobulin ( $\beta$ 2m), and antigen-processing machinery molecules was performed in 37 primary MAP carcinomas and nine metastases resected from 29 MAP patients. Furthermore, we sequenced the  $\beta$ 2m, TAP1, and TAP2 genes. Defects in HLA class I expression were detected in 65% of primary MAP carcinomas, affecting 72% of patients.

HLA class I expression abnormalities were often concomitant with  $\beta$ 2m expression loss and mutations in the  $\beta$ 2m gene. Loss of HLA class I expression is thus a frequent event in MAP carcinomas, similarly to MMR-deficient colorectal tumours. The extensive mutagenic background of these tumours most likely triggers a strong selective pressure, exerted by the immune system on the tumour, which favours the outgrowth of tumour cell clones with an immune evasive phenotype. Our data provide additional evidence for a link between DNA repair deficiencies and altered HLA class I phenotypes in colorectal cancer.

## INTRODUCTION

During cancer development, tumour cells may elicit cytotoxic T-lymphocyte-mediated immune responses — partly a consequence of accumulated gene mutations that are translated into altered peptides.<sup>1,2</sup> Tumour cell expression of the human leukocyte antigen (HLA) class I-antigen complexes is essential for T-cell recognition of aberrant peptides and subsequent activation.<sup>3</sup> Consequently, alteration of HLA class I cell surface expression provides an effective mechanism by which tumours can escape detection by immune cells.<sup>4,5</sup> Multiple mechanisms have been shown to underlie defects in HLA class I expression by tumour cells; they include mutations in the individual HLA class I genes, *HLA-A*, *-B*, and *-C*, located on chromosome 6p21.3;<sup>6</sup> loss of heterozygosity (LOH) at 6p21.3;<sup>7</sup> mutations in  $\beta$ 2-microglobulin ( $\beta$ 2m),<sup>8,9</sup> the molecule required for the cell surface expression of HLA class I antigens; and defects in components of the HLA class I-associated antigen-processing machinery.<sup>10–12</sup> The antigen-processing machinery consists of the proteasome components delta, MB1, and Z; the immunoproteasome components LMP2, LMP7, and LMP10; the peptide transporters TAP1 and TAP2; and the chaperones calnexin, calreticulin, ERp57, and tapasin. The immunoproteasome mostly, although not exclusively, generates peptides from endogenous proteins. TAP1 and TAP2 facilitate peptide translocation from the cytosol into the lumen of the endoplasmic reticulum, where the peptides are loaded onto the HLA class I molecules with the aid of several chaperones.<sup>13</sup>

232

We and others have previously described a higher frequency of HLA class I defects in colorectal cancers presenting with DNA mismatch-repair (MMR) deficiency, in comparison with MMR-proficient tumours.<sup>12,14,15</sup> Furthermore, we found that distinct molecular events underlie HLA class I loss, depending on the aetiology of the tumours; Lynch syndrome-related cancers presented with mutations in the  $\beta$ 2m molecule, while sporadic microsatelliteunstable tumours mainly showed alterations in the antigen-processing machinery components.<sup>12</sup>

Microsatellite instability is a form of genetic instability that occurs in about 15% of colorectal cancers. Microsatellite-unstable sporadic tumours have a phenotype resulting from the epigenetic inactivation of the MMR gene *hMLH1*.<sup>16</sup> Microsatellite instability is also the hallmark of Lynch syndrome-related tumours, in which germline mutations of the MMR genes *hMLH1*, *hMSH2*, *hMSH6*, and *PMS2* can be found.<sup>17</sup> Their inactivation destroys a cell's ability to repair base–base mismatches and small insertions or deletions in repetitive stretches, leading to an accumulation of frameshift mutations that become translated into abnormal peptide sequences.<sup>18</sup> These tumours are therefore thought to be more able to stimulate a cytotoxic T-cell-mediated immune

response, due to their frequent generation of aberrant peptides.<sup>19,20</sup> Consequently, these tumours are probably subjected to a selective pressure that favours the outgrowth of tumour cells with the ability to escape from recognition and destruction by the host immune system.

Another colorectal cancer syndrome in which DNA repair deficiencies are implicated is *MUTYH*-associated polyposis (MAP).<sup>21</sup> MAP is a recessive inheritable disease caused by bi-allelic *MUTYH* inactivating germline mutations.<sup>22</sup> Carriers may develop 10–500 polyps until the fifth decade of their lives and most of these patients will present with a colorectal cancer.<sup>23,24</sup> The *MUTYH* protein is a base excision repair enzyme involved in the repair of one of the most frequent and stable forms of nucleotide oxidative damage: 8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxodG). This structure readily mispairs with adenosine residues, leading to G:C>T:A transversions after DNA replication.<sup>25</sup> *MUTYH* acts by scanning the daughter DNA strand for any mispaired adenines, either with guanines or 8-oxodG's, and subsequently excising them.<sup>26</sup> Defects in this repair mechanism incapacitate the cell's ability to reverse such mispairs, leading to an accumulation of mutations. The *APC* and *KRAS* genes are frequently mutated in MAP tumours, although not exclusively presenting the typical transversions.<sup>21,27,28</sup>

We hypothesized that, similarly to MMR-deficient tumours, MAP tumours could be more prone to stimulate a cytotoxic T-cell-mediated immune response, due to their frequent generation of aberrant peptides. Hence, these tumours could also be subjected to a strong selective pressure favouring the outgrowth of cancer cells that acquire an immune evasive phenotype.

We aimed to study the occurrence of HLA class I expression deficiencies in MAP carcinomas, as well as the expression of HLA class I chaperones and antigen-processing machinery components. Furthermore, we investigated the occurrence of mutations in  $\beta 2m$  or antigen-processing machinery components when their expression was lost.

## MATERIALS AND METHODS

### Patient material

Patients were recruited throughout The Netherlands. Germline DNA mutation analysis of the whole *MUTYH* gene was performed on lymphocytic DNA or DNA from formalin-fixed, paraffin-embedded normal tissue as described previously.<sup>29,30</sup> Informed consent was obtained according to protocols approved by the LUMC ethics review board (02–2004). A tissue microarray was constructed as reported previously<sup>31</sup> and contained carcinoma tissue from 37 primary carcinomas and nine metastases (one lymph node

and eight distant metastases), derived from 29 MAP patients, represented by more than four (mean = 4.5, SD = 1.7) 0.6-mm-diameter tissue cores. Such a number of tissue cores was shown to be sufficient to account for tumour heterogeneity and thus produce reliable results.<sup>32</sup> The tissue array also included 14 adenomas resected from the above patients. The cohort's age mean was 51.2 years old (SD = 9.9). The majority of primary carcinomas were localized in the right-sided colon (73%) and the remaining had a sigmoid/rectum localization. Tumours were staged according to Dukes' classification: one was Dukes' A, 22 B, six C, and six D (three patients; one patient presented with four primary tumours and one distant metastasis). Patient samples were handled according to the medical ethical guidelines described in the Code Proper Secondary Use of Medical Sciences ([www.federa.org](http://www.federa.org)).

### Immunohistochemistry

Standard three-step, indirect immunohistochemistry was performed on 4  $\mu$ m tissue sections transferred to glass slides using a tape-transfer system (Instrumedics, Hackensack, NJ, USA), including citrate antigen retrieval (citrate buffer, pH 6.0), blockage of endogenous peroxidase and endogenous avidin-binding activity, and diaminobenzidine development.

The following primary antibodies were used: the monoclonal antibody (MAb) HCA2, which recognizes  $\beta$ 2m-free HLA-A (except -A24), -B7301, and -G heavy chains;<sup>33,34</sup> the MAb HC10, which recognizes a determinant expressed on all  $\beta$ 2m-free HLA-B and -C heavy chains and on  $\beta$ 2m-free HLA-A10, -A28, -A29, -A30, -A31, -A32, and -A33 heavy chains [33,35]; TAP1-specific MAb NOB1; LMP2-specific MAb SY-1; LMP7-specific MAb HB2; LPM10-specific MAb TO-7; calnexin-specific MAb TO-5; calreticulin-specific MAb TO11; tapasin-specific MAb TO-3; ERp57-specific MAb TO-2;<sup>36-38</sup> TAP2-specific MAb (BD Biosciences Pharmingen, San Diego, CA, USA); rabbit anti- $\beta$ 2m polyclonal Ab (A 072; DAKO Cytomation, Glostrup, Denmark); and anti-granzyme B (clone 11F1; Novocastra Laboratories, Newcastle upon Tyne, UK). Secondary reagents used were biotinylated rabbit anti-mouse IgG antibodies (DAKO Cytomation), goat anti-rabbit IgG antibodies (DAKO Cytomation), and biotinylated-peroxidase streptavidin complex (SABC; DAKO Cytomation).

All antigen-processing machinery components' antibodies, except TAP2 MAb, were kindly provided by Dr Soldano Ferrone (Roswell Park Cancer Institute, Buffalo, NY, USA). Loss of expression was defined as a complete lack of staining in the membrane and cytoplasm (HCA2, HC10, and anti- $\beta$ 2m), in the peri-nucleus/endoplasmic reticulum (NOB1, anti-TAP2, TO-2, TO-3, TO-5, TO7, and TO-11), or in the cytoplasm (SY-1, HB2, and TO-7), but with concurrent staining in normal epithelium, stroma or infiltrating leukocytes.

### ***β2m, TAP1, and TAP2* sequencing**

The *β2m*, *TAP1*, and *TAP2* genes were screened for mutations in their coding regions. DNA was isolated from three 0.6-mm-diameter tissue cores retrieved from a tissue block after evaluation of the corresponding haematoxylin and eosin-stained tissue slide. After dewaxing, the tissue cores were incubated overnight at 56 °C in 0.3 ng/μl proteinase K and purified the next day with the Genomic Wizard kit (Promega, Leiden, The Netherlands). PCR was performed in a 25 μl volume containing 20 μM of primer pair and 12 ng of sample DNA. 18mer M13-derived oligos were added to the 5' end of each primer in order to facilitate sequence analysis. Primer sequences are available as Supplementary data (see Supporting information). Amplified products were sequenced at The Leiden Genome Technology Center (Leiden, The Netherlands).

## **RESULTS**

### **HLA class I, *β2m*, and antigen-processing machinery components' expression**

Defects in HLA class I expression were detected in 24/37 primary carcinomas and in all nine tumour metastases (seven of which derived from patient 29), comprising 72% of the patients included in the study (Table 1). The HCA2 and HC10 antibodies detect the expression of HLA-A and HLA-B, -C, respectively. Within the group of tumours with HLA class I defects, six primary carcinomas (25%) presented with total loss of HLA class I (concomitant loss of HCA2 and HC10); another two carcinomas (8%) presented with loss of solely the HLA-A molecule (as assessed with HCA2 antibody); and the remaining carcinomas (67%) presented heterogeneous patterns with alternating positive and negative tumour areas for HLA class I expression (Figure 1). All seven metastases from patient 29 expressed HLA class I, although no membranous expression was detectable with the HCA2 antibody (Figure 1).

We also investigated the concurrent loss of expression of *β2m* and antigen-processing machinery components with that of HLA class I. Loss of *β2m* expression was detected in 58% of carcinomas with HLA class I expression abnormalities (Table 1); four of these presented with total loss of HLA class I (Figure 2B), two exclusively lost HLA-A expression, and eight cases possessed a heterogeneous pattern of HLA class I expression (Figures 2C and 2D) normally accompanied by a similar pattern of *β2m* expression. This heterogeneous pattern was frequently recognized within one tissue core, as represented in Figures 2C and 2D. Notably, the seven tumour metastases from patient 29, presenting with a peri-nuclear pattern of expression for HLA class I, showed total absence of *β2m* expression, further confirming the existence of HLA class I expression abnormalities (Figures 2E and 2F).

**Table I.** Expression of HLA class I,  $\beta$ 2m, and antigen-processing machinery components in MAP carcinomas

| MAP carcinomas            | HLA class I expression       | $\beta$ 2m loss | APM loss       |
|---------------------------|------------------------------|-----------------|----------------|
| Primary tumours<br>n = 37 | + 13 (35.1%)<br>- 24 (64.9%) | 0<br>14 (58.3%) | 0<br>4 (16.7%) |
| Metastases<br>n = 9*      | + 0<br>- 9                   | 0<br>8          | 0<br>1         |

- = altered expression in tumour cells.  
\* Seven of the nine metastases belonged to one patient.

| Patient | Tumour | Metastases | HCA2                | HCI10              | $\beta$ 2M         | APM                               | $\beta$ 2m mutation   | APM mutation                       |
|---------|--------|------------|---------------------|--------------------|--------------------|-----------------------------------|-----------------------|------------------------------------|
| 1       | 1      |            | +                   | +                  | +                  | +                                 | c.17 C>T (Ala6Val)    |                                    |
|         | 2      |            | 0 <sup>+</sup> het  | +                  | 0 <sup>+</sup> het | +                                 |                       |                                    |
|         | 3      |            | 0 <sup>+</sup> het  | 0 <sup>+</sup> het | 0 <sup>+</sup> het | +                                 |                       |                                    |
|         | 4      |            | 0 <sup>+</sup> het  | 0 <sup>+</sup> het | +                  | +                                 |                       |                                    |
| 2       | 1      |            | 0 <sup>+</sup> het  | +                  | 0 <sup>+</sup> het | +                                 | c.323C>A (Ser107Stop) |                                    |
|         | 2      |            | 0 <sup>+</sup> het  | +                  | +                  | +                                 |                       |                                    |
| 3       |        |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 4       |        |            | 0 <sup>+</sup>      | 0 <sup>+</sup>     | 0 <sup>+</sup> het | +                                 |                       |                                    |
| 5       |        |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 6       |        |            | 0 <sup>+</sup> het  | 0 <sup>+</sup> het | 0 <sup>+</sup> het | +                                 |                       |                                    |
| 7       |        |            | 0 <sup>+</sup> het  | 0 <sup>+</sup> het | 0 <sup>+</sup> het | +                                 |                       |                                    |
| 8       |        |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 9       |        |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 10      |        |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 11      |        |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 12      |        |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 13      |        |            | 0 <sup>+</sup> het  | 0 <sup>+</sup> het | +                  | +                                 |                       |                                    |
| 14      |        |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 15      |        |            | 0 <sup>+</sup> het* | +                  | 0 <sup>+</sup>     | +                                 |                       |                                    |
| 16      |        |            | 0 <sup>+</sup> het  | +                  | +                  | 0 <sup>+</sup> (TAP2)             |                       |                                    |
| 17      | 1      |            | +                   | +                  | +                  | +                                 |                       |                                    |
|         | 2      |            | 0 <sup>+</sup> het  | 0 <sup>+</sup> het | 0 <sup>+</sup> het | +                                 |                       |                                    |
| 18      |        |            | 0 <sup>+</sup> het  | 0 <sup>+</sup> het | +                  | +                                 |                       |                                    |
| 19      |        |            | 0 <sup>+</sup> het  | 0 <sup>+</sup>     | +                  | +                                 |                       |                                    |
| 20      |        |            | 0 <sup>+</sup>      | 0 <sup>+</sup>     | 0 <sup>+</sup>     | +                                 |                       |                                    |
| 21      | 1      |            | 0 <sup>+</sup>      | +                  | +                  | 0 <sup>+</sup> (TAP2)             |                       |                                    |
|         | 2      |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 22      | 1      |            | 0 <sup>+</sup> het  | 0 <sup>+</sup> het | +                  | +                                 | c.199G>A (Glu64Lys)   |                                    |
|         | 2      |            | 0 <sup>+</sup> het  | 0 <sup>+</sup> het | 0 <sup>+</sup> het | +                                 |                       | c.4T>G (Ser2Ala) c.14T>A (Val5Glu) |
|         | 3      |            | 0 <sup>+</sup>      | 0 <sup>+</sup>     | 0 <sup>+</sup>     | +                                 |                       |                                    |
| 23      | 1      |            | 0 <sup>+</sup> het  | +                  | 0 <sup>+</sup> het | +                                 |                       |                                    |
|         | 2      |            | +                   | +                  | +                  | +                                 |                       |                                    |
| 24      | 1      |            | 0 <sup>+</sup>      | +                  | 0 <sup>+</sup>     | +                                 | c.37_38insCC          |                                    |
| 25      | 1      |            | 0 <sup>+</sup>      | 0 <sup>+</sup>     | +                  | 0 <sup>+</sup> (TAP1)             |                       |                                    |
|         | 1      |            | 0 <sup>+</sup>      | 0 <sup>+</sup>     | +                  | 0 <sup>+</sup> (TAP1, TAP2)       | c.148T>A (Phe49Ile)   | c.416G>A (Trp139Stop)              |
| 26      | 1      |            | 0 <sup>+</sup>      | 0 <sup>+</sup>     | +                  | 0 <sup>+</sup> (TAP1, TAP2, Tpsn) |                       |                                    |
| 27      | 1      |            | +                   | +                  | +                  | +                                 |                       |                                    |
|         | 2      |            | 0 <sup>+</sup> het  | +                  | 0 <sup>+</sup>     | +                                 | c.68-2A>G             |                                    |
| 28      | 1      |            | 0 <sup>+</sup>      | 0 <sup>+</sup>     | 0 <sup>+</sup>     | +                                 |                       |                                    |
| 29      | 1      |            | 0 <sup>+</sup> het* | +                  | 0 <sup>+</sup>     | +                                 | c.1A>T (Met1Leu)      |                                    |
|         | 2      |            | 0 <sup>+</sup> het* | +                  | 0 <sup>+</sup>     | +                                 | c.1A>T (Met1Leu)      |                                    |
|         | 3      |            | +                   | +                  | 0 <sup>+</sup>     | +                                 | c.1A>T (Met1Leu)      |                                    |
|         | 4      |            | 0 <sup>+</sup> het* | +                  | 0 <sup>+</sup>     | +                                 | c.1A>T (Met1Leu)      |                                    |
|         | 5      |            | +                   | +                  | 0 <sup>+</sup>     | +                                 | c.1A>T (Met1Leu)      |                                    |
|         | 6      |            | 0 <sup>+</sup> het* | +                  | 0 <sup>+</sup>     | +                                 | c.1A>T (Met1Leu)      |                                    |
|         | 7      |            | 0 <sup>+</sup> het* | +                  | 0 <sup>+</sup>     | +                                 | c.1A>T (Met1Leu)      |                                    |

**Figure 1.** Expression of HLA class I was detected with HCA2 (HLA-A) and HCI10 (HLA-B, HLA-C) antibodies. Additionally, the expression of the chaperone  $\beta$ 2-microglobulin and the antigen-processing machinery components were determined. + = positive; 0<sup>+</sup> = loss of expression with internal positive control; 0<sup>0</sup> = loss of expression without internal positive control; 0<sup>+</sup> het = heterogeneous expression, with positive and negative tumour cells; +\* = non-membranous (cytoplasmic HLA class I expression); 0<sup>+</sup> het\* = heterogeneous expression, with positive (cytoplasmic HLA class I expression) and negative tumour cells.  $\beta$ 2m mutations were investigated in all cases where DNA was available, and TAP1 and TAP2 mutations were screened when one of these molecules was not expressed. - = No mutations found with the complete gene sequence available



Concurrent loss of antigen-processing machinery components and HLA class I expression was observed in five cases: four primary tumours (17% of tumours with HLA class I expression abnormalities) and one tumour metastasis (Table 1). *TAP1* and/or *TAP2* were lost in all of these cases, while tapasin was found to be abrogated in patient 26 (Figure 1). Except for the latter, all other tumour tissues failed to present a clear internal positive control, thus not allowing the confirmation of loss of expression of those molecules. Loss of expression of the antigen-presenting machinery components and  $\beta 2m$  was mutually exclusive.

Fourteen adenomas, from ten patients, were analysed for HLA class I and  $\beta 2m$  expression. Only three (21%) displayed aberrant HLA class I expression which was always heterogeneous throughout the adenomatous tissue. All three belonged to patients with HLA class I deficiencies in at least one of their carcinomas. Loss of expression of  $\beta 2m$  was found in one of the adenomas with HLA class I deficiencies.

#### **$\beta 2m$ , *TAP1*, and *TAP2* sequencing**

We sequenced the coding regions of the  $\beta 2m$ , in all tumours for which DNA was available, and *TAP1* and *TAP2* genes in the tumours that lacked expression of these molecules. All mutations are listed in Figure 1. Mutations in  $\beta 2m$  were identified in eight primary carcinomas. In one case (patient 1, tumour 1), the mutation was not related to loss of either  $\beta 2m$  or HLA class I expression. Two other tumours conserved  $\beta 2m$  expression but presented deficiencies in HLA class I expression (patient 2 and patient 22, tumour 1). The remaining all had detectable defective  $\beta 2m$  expression. Eight metastases with HLA class I loss of expression carried a mutation in the  $\beta 2m$  gene. All seven belonging to patient 29 presented with the same mutation in the starting codon of the  $\beta 2m$  gene (c.1A > T). Starting-codon, splice-site or frameshift mutations were associated with loss of  $\beta 2m$  expression. The carcinoma from patient 2 displayed a truncating mutation in the 3. end of the gene which did not lead to abrogation of  $\beta 2m$  expression. Amino-acid substitutions were associated with retained  $\beta 2m$  expression and in one case, a heterogeneous pattern of expression (patient 22, tumour 2). The complete  $\beta 2m$  sequence was available for six additional tumours without HLA class I/  $\beta 2m$  aberrations and no mutations were found. Only one mutation was found in the peptide transporters. Patient 25 presented an early STOP codon in the third exon of the *TAP2* gene. The usage of formalin-fixed material for DNA extraction did not always allow full gene sequencing for all cases, implying a possible underestimation of the number of samples carrying mutations.


## DISCUSSION

Defects in HLA class I expression defects have been frequently reported in several cancers.<sup>5,6,10,11,39</sup> These are interpreted as mechanisms adopted by tumours to escape immune surveillance and thereby avoid tumour cell recognition and destruction. We, and others, have previously described a predisposition for MMR-deficient colorectal tumours to lose HLA class I expression.<sup>12,14,15</sup> MMR-deficient tumours are thought to be more competent at triggering an immune response, due to their increased mutagenic potential, when compared with MMR-proficient tumours, which translates into an accumulation of frameshift peptides that might work as tumour neo-antigens<sup>8,19,20</sup>. The immune reaction might function as a selective pressure that favours the outgrowth of tumour cell clones that have lost HLA class I expression. In the present work, we investigated the occurrence of HLA class I expression deficiencies in MAP carcinomas. Patients with MAP carry biallelic mutations in the *MUTYH* gene, which prevents the cells from accumulating point mutations derived from DNA oxidative damage. Like Lynch syndrome and sporadic MSI-H tumours, one would expect that MAP carcinomas would be competent at triggering immune responses and would be similarly subjected to a selective pressure, imposed by the immune system, favouring the outgrowth of cells with absent HLA class I expression.

238

We identified HLA class I expression abnormalities in the majority of MAP carcinomas analysed, both in the primary carcinomas and in the tumour metastases. In total, 72% of patients carried carcinomas (68% of primary tumours) that exhibited HLA class I expression deficiencies. Previously, we described that approximately half of MSI-H sporadic tumours and Lynch syndrome-related tumours had defects in HLA expression, while colon mismatch-repair-proficient tumours presented HLA class I expression abnormalities in only a minority of the carcinomas analysed (17%).<sup>12</sup> Put together, these observations provide additional evidence of the prevalence of HLA class I expression alterations in tumours carrying defects in DNA-repairing molecules. Furthermore, we analysed 14 adenomas from the same cohort of patients for HLA class I and  $\beta 2m$  expression but these were seldom, as was previously reported for colorectal adenomas.<sup>40</sup> The increased mutagenic load and cytotoxic T-cell infiltration of carcinomas probably constitute an environment with greater selective pressure for immune evasive events than at adenoma stages.

Intriguingly, the majority of defects found in MAP carcinomas were in the form of heterogeneous patterns of HLA class I expression within the tumours, suggesting that MAP carcinomas are composed of different clones with respect to HLA class I expression. Such a phenotype was not observed in MSI-H tumours (data not shown).



**Figure 2.** (A) Immunohistochemical detection of HLA class I expression with HCA2 antibody in the carcinoma from patient 11, displaying membranous expression in tumour cells. (B) HLA class I-negative carcinoma (large arrow) with positive internal control (small arrow) (patient 28). (C, D) Heterogeneous pattern of HLA class I expression; focal loss of HLA class I expression (large arrow) presented together with positive membranous expression (small arrow) (C, patient 17, tumour 2; D, patient 22, tumour 1). (E) Cytoplasmic accumulation of HLA class I in a case with  $\beta$ 2m loss of expression, depicted in F (patient 29, metastases 4)

We previously reported that MAP carcinomas frequently display multiclonality for DNA content,<sup>41,42</sup> further supporting our observations. One piece of circumstantial evidence for increased immunogenicity of MMR-deficient tumours is the dense infiltration of the epithelial compartments of MSI-H carcinomas by T-cells, a hallmark of the histopathology of MMR-deficient tumours.<sup>43,44</sup> We also observed a higher incidence of moderate/marked infiltration by T-cells in the epithelium of MAP carcinomas, when compared with microsatellite-stable tumours (data not shown).

In the work of Dierssen *et al*, we dissected the most common mechanisms by which HLA class I expression was altered in sporadic MSI-H and hereditary (Lynch syndrome) MMR-deficient tumours.<sup>12</sup> We found that  $\beta 2m$  mutations occurred preferentially in Lynch syndrome tumours, while sporadic MSI-H tumours presented more frequently with deficiencies at the level of the antigen-processing machinery components. Kloor *et al* also reported that mutations in the  $\beta 2m$  gene occurred more frequently in Lynch syndrome-derived tumours than in sporadic MSI-H tumours.<sup>9</sup> We investigated whether the loss of any of these molecules was coupled to HLA class I expression deficiencies in MAP carcinomas; expression of  $\beta 2m$  was absent in 58% of MAP primary carcinomas with altered HLA class I expression, while at least one of the antigen-processing machinery components was not detected in 18% of MAP carcinomas with HLA class I alterations. Although speculative, it is interesting to underline that carcinomas derived from both MAP and Lynch syndromes preferentially lose  $\beta 2m$  expression coupled to HLA class I deficiencies. A functional explanation for these observations remains elusive, but perhaps distinct reactions (both qualitative and quantitative) by the immune system, depending on the age of onset of the tumours, could condition the type of mechanisms that lead to HLA class I expression deficiencies.

240

Middeldorp *et al* reported extensive chromosomal recombination events in MAP carcinomas.<sup>41</sup> These frequently translate into LOH with maintenance of chromosome copy number (copy neutral LOH) throughout the genome. LOH at chromosome 6p21 (*HLA locus*) and 15q22–23 ( $\beta 2m$  locus) was frequently detected, but no association with HLA class I or  $\beta 2m$  expression was found (data not shown). In cases with maintenance of HLA class I expression, LOH at 6p might conceal an alternative HLA class I phenotype, not identified by immunohistochemistry: loss of one parental haplotype and amplification of the other. Each HLA class I haplotype has distinct affinities to different antigens, based on their peptide sequence. Therefore, the loss of one haplotype excuses the tumour cell from presenting a specific pool of peptides to the immune system. Moreover, the maintenance of one parental haplotype allows recognition of the 'self' by the immune cells and might impede the destruction of tumour cells by natural killer (NK) cells.<sup>4</sup> No polymorphisms in  $\beta 2m$  have been associated with different efficiencies in peptide presentation; it is therefore difficult to determine whether LOH in 15q, in cases without HLA class I abnormalities, has any effect on HLA class I/antigen presentation.

The high frequency of alterations in HLA class I expression in MMR-deficient and in MAP carcinomas constitutes a strong handicap for the employment of Tcell-based immunotherapy on advanced tumours.<sup>45</sup> On the other hand, the fact that the immune

system is able to recognize tumour antigens during cancer development reveals an opportunity for the development of vaccination strategies based on frequently altered peptides across different MAP carcinomas.<sup>46,47</sup> Additionally, memory T-cell responses could be used in the diagnostic setting, if they occurred at an early stage of tumour development, thus adding possibilities for the development of less invasive screening techniques, especially in carriers of hereditary syndromes.

We are the first to report HLA class I abnormalities in MAP carcinomas. It provides additional evidence that tumours carrying defects in DNA base repair mechanisms are more prone to undergo immune escape mechanisms. With this work, all known syndromes and subsets of sporadic colorectal tumours arising in the context of DNA repair deficiencies have now been linked with higher frequencies of HLA class I abnormalities, when compared with DNA base repair-proficient tumours.

## References

1. Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, *et al.* Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. *Clin Cancer Res* 2006;12:1365–1372.
2. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. *Annu Rev Immunol* 2006;24:175–208.
3. Stevanovic S, Schild H. Quantitative aspects of T cell activation — peptide generation and editing by MHC class I molecule. *Semin Immunol* 1999;11:375–384.
4. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. *Cancer Immunol Immunother* 2004;53:904–910.
5. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. *Cancer Immunol Immunother* 2007;56:227–236.
6. Koopman LA, van der Slik AR, Giphart MJ, Fleuren GJ. Human leukocyte antigen class I gene mutations in cervical cancer. *JNatl Cancer Inst* 1999;91:1669–1677.
7. Maleno I, Cabrera CM, Cabrera T, Paco L, Lopez-Nevot MA, Collado A, *et al.* Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. *Immunogenetics* 2004;56:244–253.
8. Bicknell DC, Kaklamani L, Hampson R, Bodmer WF, Karran P. Selection for beta(2)-microglobulin mutation in mismatch repair-defective colorectal carcinomas. *Curr Biol* 1996;6:1695–1697.
9. Kloor M, Michel S, Buckowitz B, Ruschoff J, Buttner R, Holinski-Feder BE, *et al.* Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. *Int J Cancer* 2007;121:454–458.
10. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. *Clin Cancer Res* 2006;12:3890–3895.
11. Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, *et al.* Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. *Clin Cancer Res* 2003;9:1721–1727.
12. Dierssen JWF, de Miranda NFCC, Ferrone S, van Puijtenbroek M, Cornelisse CJ, Fleuren GJ, *et al.* HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. *BMC Cancer* 2007;7:33.
13. Koch J, Tampe R. The macromolecular peptide-loading complex in MHC class I-dependent antigen presentation. *Cell Mol Life Sci* 2006;63:653–662.
14. Dierssen JW, de Miranda N, Mulder A, van Puijtenbroek M, Verduyn W, Claas F, *et al.* High-resolution analysis of HLA class I alterations in colorectal cancer. *BMC Cancer* 2006;6:233.
15. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, *et al.* Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. *Cancer Res* 2005;65:6418–6424.
16. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, *et al.* Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. *Cancer Res* 1998;58:3455–3460.
17. Umar A, Risinger JI, Hawk ET, Barrett JC. Guidelines — testing guidelines for hereditary non-polyposis colorectal cancer. *Nature Rev Cancer* 2004;4:153–158.
18. Johannsdottir JT, Jonasson JG, Bergthorsson JT, Amundadottir LT, Magnusson J, Egilsson V, *et al.* The effect of mismatch repair deficiency on tumorigenesis; microsatellite instability affecting genes containing short repeated sequences. *Int J Oncol* 2000;16:133–139.
19. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, *et al.* Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. *Int J Cancer* 2001;93:6–11.

20. Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, Doeberitz MV. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. *Cancer Immunity* 2004;4:14.
21. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, *et al.* Inherited variants of MYH associated with somatic G : C T : A mutations in colorectal tumors. *Nature Genet* 2002;30:227–232.
22. Sampson J, Jones S, Seiber O, Lipton L, Maynard J, Al-Tassan N, *et al.* An autosomal recessive multiple colorectal adenoma and carcinoma syndrome caused by inherited mutations in MYH. *JMed Genet* 2002;39:S15.
23. Chow E, Thirlwell C, Macrae F, Lipton L. Colorectal cancer and inherited mutations in base-excision repair. *Lancet Oncol* 2004;5:600–606.
24. Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RKS, *et al.* Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N Engl JMed* 2003;348:791–799.
25. Nakabeppu Y, Tsuchimoto D, Furuichi M, Sakumi K. The defense mechanisms in mammalian cells against oxidative damage in nucleic acids and their involvement in the suppression of mutagenesis and cell death. *Free Radic Res* 2004;38:423–429.
26. Shinmura A, Yamaguchi S, Saitoh T, Takeuchi-Sasaki M, Kim SR, Nohmi T, *et al.* Adenine excisional repair function of MYH protein on the adenine : 8-hydroxyguanine base pair in double-stranded DNA. *Nucleic Acids Res* 2000;28:4912–4918.
27. Lipton L, Halford SE, Johnson V, Novelli MR, Jones A, Cummings C, *et al.* Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. *Cancer Res* 2003;63:7595–7599.
28. Jones S, Lambert S, Williams GT, Best JM, Sampson JR, Cheadle JP. Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas. *Br J Cancer* 2004;90:1591–1593.
29. Nielsen M, Franken PF, Reinards THCM, Weiss MM, Wagner A, van der Klift H, *et al.* Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). *JMed Genet* 2005;42:e54.
30. van Puijenbroek M, Nielsen M, Tops CM, Halfwerk H, Vasen HF, Weiss MM, *et al.* Identification of patients with (atypical) *MUTYH*-associated polyposis by *KRAS2* c.34G > T prescreening followed by *MUTYH* hotspot analysis in formalin-fixed paraffin-embedded tissue. *Clin Cancer Res* 2008;14:139–142.
31. van Puijenbroek M, van Asperen CJ, van Mil A, Devilee P, van Wezel T, Morreau H. Homozygosity for a CHEK2\* 1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. *J Pathol* 2005;206:198–204.
32. Goethals L, Perneel C, Debucquoy A, De Schutter H, Borghys D, Ectors N, *et al.* A new approach to the validation of tissue microarrays. *J Pathol* 2006;208:607–614.
33. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. *J Immunol* 1986;137:2299–2306.
34. Sernee MF, Ploegh HL, Schust DJ. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. *Mol Immunol* 1998;35:177–188.
35. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. {Beta}2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. *J Immunol* 2003;171:1918–1926.
36. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. *Tissue Antigens* 2003;62:385–393.

37. Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, *et al.* Development and characterization of human constitutive J Pathol 2009; 219: 69–76 DOI: 10.1002/path Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005;66:185–194.
38. Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, *et al.* A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 2005;299:139–151.
39. Cabrera T, Collado A, Fernandez MA, Ferron A, Sancho J, Ruiz-Cabello F, *et al.* High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 1998;52:114–123.
40. Jackson PA, Green MA, Marks CG, King RJB, Hubbard R, Cook MG. Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Gut 1996;38:85–89.
41. Middeldorp A, van Puijtenbroek M, Nielsen M, Corver WE, Jordanova ES, Tops CMJ, *et al.* High frequency of copy neutral LOH in *MUTYH*-associated polyposis carcinomas. EJC Suppl 2008;6:114–115.
42. Corver WE, ter Haar NT, Dreef EJ, Miranda NFCC, Prins FA, Jordanova ES, *et al.* High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopulations in paraffin-embedded tissues. J Pathol 2005;206:233–241.
43. Phillips AB. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004;91:469–475.
44. Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, *et al.* High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999;154:1805–1813.
45. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002;20:A40–A45.
46. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, *et al.* Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008;134:988–997.
47. Speetjens FM, Kuppen PJ, Morreau H, van der Burg SH. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008;135:711–712.



